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Resumen
Objetivo: Conocer aquellos factores predictivos de hiperglucemia que 
orienten al diseño de una nutrición parenteral de inicio que nos permita evitar 
posteriores complicaciones asociadas a la misma. 
Métodos: Se diseñó un estudio prospectivo observacional en el que se 
incluyeron los pacientes adultos hospitalizados con nutrición parenteral total 
por vía central con al menos 48 horas de duración; se realizó un seguimien-
to nutricional y farmacoterapéutico según la práctica habitual; se recogieron 
variables demográficas, clínicas, analíticas y relacionadas con la nutrición y 
la farmacoterapia. 
Resultados: Se incluyeron 58 pacientes, se intervino con restricción de 
glucosa en 28 pacientes (48,3%). Esta intervención se asoció de manera 
estadísticamente significativa a glucemia elevada previa a la nutrición pa-
renteral (OR: 1,38; IC 95% 1,11-1,73, p = 0,004) e IMC (OR: 1,29; IC 95% 
1,05-1,58, p = 0,014), siendo más frecuente la intervención en los pacien-
tes con IMC > 25 (sobrepeso y obesidad) (OR: 10,00; IC 95% 1,15-86,95, 
p = 0,037). 
Conclusiones: Los valores de glucemia previos a la nutrición parenteral, 
la diabetes y los valores de IMC > 25 son predictores de hiperglucemia; por 
tanto, una temprana intervención para prevenir y corregir la hiperglucemia 
podría mejorar los resultados clínicos en pacientes con nutrición parenteral.
Abstract
Objective: To know those predictive factors of hyperglycemia that could 
guide us the design of a parenteral nutrition and it could avoid later com-
plications associated with it. 
Methods: A prospective observational study was designed; adult hos-
pitalized patients who received total parenteral nutrition at least 48 hours 
were included. Nutritional and pharmacotherapeutic follow-up were per-
formed according to usual practice. Variables collected included demo-
graphic, clinical, analytical and nutrition and pharmacotherapy. 
Results: Fifty-eight patients were included, with 28 patients (48.3%) with 
glucose restriction. This intervention was statistically associated with ele-
vated glycemia prior to parenteral nutrition (OR: 1.38, 95% CI 1.11-1.73, 
p = 0.004) and BMI (OR: 1.29, 95% CI 1.05-1.58, p = 0.014), with more 
frequent intervention was in patients with BMI > 25 (overweight and obe-
se) (OR: 10.00; 95% CI 1.15-86.95, p = 0.037). 
Conclusions: Pre-parenteral glycemic values, diabetes and BMI va-
lues > 25 are predictors of hyperglycemia, so a early intervention to pre-
vent and correct hyperglycemia may improve clinical outcomes in patients 
with parenteral nutrition.
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Introduction
Parenteral nutrition (PN) maintains an adequate nutritional status, which 
is important in order to improve disease prognosis and sustain an ap-
propriate immune system1,2. The beneficial effects of PN have been well 
established, but some studies have questioned its safety due to the risk of 
derived complications, such as hyperglycemia, with an incidence ranging 
from 10 to 88% according to literature1,3-6.
PN is associated with a higher frequency of hyperglycemia and insu-
lin requirements7 because glucose in NP will go straight into peripheral 
circulation, reaching high systemic levels, but remaining low in portal cir-
culation3. On the other hand, there is an increase in metabolic pathways 
(gluconeogenesis and glycogenolysis) mediated by hormonal regulation 
and proinflammatory cytokines2,8. As a consequence, there is sustained 
hyperglycemia together with hyperinsulinemia and various side effects 
such as hyperosmolarity, glycosuria, excess of CO2, liver impairment, 
etc.3.
Critical patients will frequently develop hyperglycemia secondary to 
stress and their hypermetabolic condition due to acute lesion3. Some non-
critical patients, even without any previous history of diabetes mellitus 
(DM) or glucose intolerance, will respond to PN with very severe hyper-
glycemia; this will subsequently entail correction through fast-acting insulin 
and the modification of the PN formulation as soon as possible9.
Hyperglycemia is a common and undesirable complication of PN, 
and it represents a good marker for results, morbidity and mortality1,4,6,10-13. 
High glucose levels in blood can lead to severe complications such as 
infections, sepsis, renal failure or respiratory failure4.
PN formulation provides glucose continuously, and therefore higher 
glucose levels in PN are associated with higher hyperglycemia14. For this 
reason, it must be ensured that each patient will receive the adequate 
intake of carbohydrates and insulin7, taking into account that nutritional 
requirements are higher in hypercatabolic states8.
Glucose restriction in PN is one of the potential strategies for glycemic 
control in patients on PN, and the one conducted in our setting; but other 
strategies have also been studied, even though without any conclusive 
outcomes, such as the combination of PN and enteral nutrition, the delay 
in PN initiation, the addition of glutamine or chromium, or the use of cer-
tain lipid emulsions in PN formulation, etc15.
Following recommendations by scientific societies, the content of glu-
cose as an energy substrate will be adjusted in order to maintain glycemic 
values below 150 mg/dl, with the required content of exogenous insu-
lin16,17. Values above 180 mg/dl might be associated with worse clinical 
results8,11,12. All this reinforces the need to achieve strict glucose control, 
because it is associated with a lower risk of complications in hospitalized 
patients9.
Previous glucose levels can orientate towards initiating a therapy with 
glucose restriction in patients with DM; however, in other non-diabetic 
patients who develop hyperglycemia, no initial restrictions will be usually 
made. Knowing the predisposing factors before PN initiation would allow 
to adapt the initial PN formulation for each individual patient, thus redu-
cing the risk of hyperglycemia and its subsequent complications9.
The primary objective of this study is to understand the predictive fac-
tors of hyperglycemia. The secondary objectives are to compare those 
patients with intervention (glucose reduction in PN) vs. those without in-
tervention, and to determine which factors are associated with a higher 
efficacy in said intervention.
Methods
A prospective observational study was designed and conducted du-
ring six months (November, 2015 to April, 2016), including consecutively 
all adult patients hospitalized (critical and non-critical) receiving total PN 
through a central line for at least 48 hours. Those patients included were 
followed up from PN initiation to its discontinuation, EN initiation, or oral 
tolerance.
Data collection
The following data were collected during the study:
Demographical variables: gender, age, weight, body mass index (BMI) 
calculated through weight (kg)/ (height (m))2.
Clinical variables:
 – Clinical Record: insulin-dependent diabetic or not, previous creatini-
ne, basal comorbidities (hypertension, dyslipidemia, heart conditions, 
COPD).
 – Reason for PN (complication of a GI tract neoplasia, abdominal sur-
gery post-operative period, GI hemorrhage, clinical deterioration due 
to sepsis, oral intolerance due to liver disease, or oral intolerance for 
other reasons).
 – Clinical or surgical condition.
 – Stay at the ICU (Intensive Care Unit) or not.
Nutrition and Drug Therapy:
 – Type of PN administered (mean volume of glucose, proteins and lipids 
administered (g/kg/24h)).
 – Basal energy expenditure (BEE) (Kcal/24h), Kcal in the PN administered 
(Kcal/24h) and association between both (proportion).
 – Need for insulin during PN: yes (subcutaneous or intravenous) or not.
 – Days until development of hyperglycemia.
 – Duration of PN (in days).
Lab Test Variables:
 – Glucose levels previous to PN (mg/dl)*.
 – Mean daily glucose levels during PN*: the daily mean value is estima-
ted from the glucose concentrations measured every 8 hours.
 – Days until glycemic normalization after glucose restriction.
*Hyperglycemia was defined as > 150mg/dl glucose levels in plasma.
Protocol for nutritional intervention
The follow-up for patients on PN was conducted according to the usual 
protocol described below.
After PN prescription, the total PN formulation was calculated based on 
the caloric and clinical needs of each patient, through the estimation of ba-
sal energy expenditure by Harris-Benedict (HB). Formulations with glucose 
restriction were initiated from the start in patients with DM:
• D1 Formulations (50 g glucose restriction from their nutritional needs).
• D2 Formulations (100 g glucose restriction from their nutritional needs).
The Pharmacy Unit conducted daily follow-up for patients on PN, taking 
into account the following premises:
 – In any case, the minimum values of glucose in the formulations were 
100 g per day.
 – In diabetic patients, PN was initiated with a restricted formulation of 
100 g glucose (D2 Formulation).
 – Blood glucose tests (with capillary glucometer) were conducted every 8 
hours since PN initiation.
 – If glucose restriction was sustained over time, daily Kcal were compen-
sated with lipids.
Glucose adjustments in PN were made according to the current protocol 
prepared by the Pharmacy Unit and the Endocrinology Unit (Figure 1). The 
mode of action consisted in the daily adjustment of glucose volume in the 
PN formulation, based on the glycemic values recorded in the 24 previous 
hours (blood glucose tests):
 – If three consecutive glucose levels > 150 mg/l or two > 180 mg/l were 
observed, there was a glucose reduction of 50 g per day, up to a mini-
mum 100 g glucose in PN.
 – If high glycemic values continued subsequently, insulin was added to PN 
(the volume was two thirds of the fast-acting insulin administered the day 
before, according to the outcomes of the sliding scale).
The PN formulations prepared were standardized according to protein 
and glucose grams; and initially contained the same volume of lipids, mi-
cronutrients and electrolytes. These were the basis for PN prescription and 
preparation, and were used as a model to modify the adjustment to the 
individual requirements of each patient according to their daily clinical and 
lab test evolution.
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Statistical Analysis
A descriptive analysis of the individual characteristics of patients was 
conducted, both in the total sample and by groups with intervention (pa-
tients who had undergone glucose reduction or insulin addition in their 
PN according to the protocol in figure 1) and without intervention. There 
was an estimation of the mean value, standard deviation, maximum and 
minimum values of quantitative variables; while qualitative or discrete va-
riables were described through absolute (N) and relative (%) frequency 
throughout the sample. A univariate logistical regression analysis was 
conducted in order to identify which individual characteristics were as-
sociated with the intervention. The odds ratio of the intervention was 
estimated in each case, as well as their 95% Confidence Interval, and 
the relevant p-value (Square Chi Test). It was decided to exclude dia-
betic patients for this analysis, because they would require intervention 
by protocol. A second stage intended to determine which individual 
factors would be associated with higher efficacy in the intervention; to 
this end, a Cox Regression Analysis was conducted, considering the time 
from intervention to stabilization as time scale, and stabilization as final 
outcome. There was an estimation of hazard ratio, its 95% Confidence 
Interval, and the relevant p-value (Square Chi Test). There was an ad-
justment by the diabetes variable in the model. The STATA (version 11) 
statistical program was used.
Results
Fifty-eight (58) patients on PN were included; there was nutritional 
and pharmacotherapeutical follow-up according to usual practice. PN 
was administered through central line to all 58 patients, with a conti-
nuous perfusion during 24 hours (not cyclic). The mean contents (± stan-
dard deviation) of carbohydrates were 2.2 (± 0.8) g/kg/day, the protein 
contents were 0.9 (± 0.3) g/kg/day, and 0.8 (± 0.3) g/kg/day of lipids. 
The mean BEE was 1402.27 (± 273.24) kcal/day, with a mean daily 
intake of 20kcal (± 7) /kg/day, which represented 99.7% of the BEE for 
each patient estimated through HB. All formulations were supplemented 
with vitamins and trace elements. There was a mean follow-up of 12 
days (from 2 to 51 days). Hyperglycemia developed in diabetic patients 
on the first day of PN administration, while for non-diabetic patients, this 
occurred after a mean 2.3 days (from 1 to 10 days).
Forty-five (45) patients (77.5% of the sample) had not been diag-
nosed with diabetes; however, 40% of them (18 patients) presented 
hyperglycemia during follow-up. There was an intervention in all diabetic 
patients, except for three patients who presented 120mg/dl glycaemia 
before PN, and it was decided not to restrict glucose to 100g. Table 1 
shows all variables collected from the 58 patients included in the study.
There was a glucose restriction intervention in 28 patients (48.3%). 
Analysis by logistical regression was conducted in two arms: 28 patients 
with intervention for alteration of glucose levels (with intervention) and 
30 patients for whom no glucose modification was conducted in their 
PN (without intervention). Given that diabetes determines intervention by 
protocol (OR: 5; CI 95% 1.21-20.77, p = 0.026), statistical analysis was 
conducted excluding diabetic patients (10 patients in the intervention 
group arm and 3 patients without intervention). Table 2 shows the outco-
mes of the logistical regression.
The intervention was associated in a statistically significant way to 
previous high glucose levels (OR: 1.38; CI 95% 1.11-1.73, p = 0.004) 
and BMI (OR: 1.29; CI 95% 1.05-1.58, p = 0.014); intervention was 
more frequent in patients with BMI > 25 (overweight and obese) (OR: 
10.00; CI 95% 1.15-86.95, p = 0.037).
Mean glucose levels during PN were higher in the intervention arm 
(OR: 1.83; CI 95% 1.24-2.72, p = 0.002), as well as insulin adminis-
tration (OR: 12.25; CI 95% 2.92-51.42, p = 0.001) and the number of 
insulin units (OR: 2.70; CI 95% 1.05-6.94, p = 0.038). A trend towards 
significance was observed in the association with intervention in patients 
with neoplasia and with the higher duration of PN. No statistical signifi-
cance was achieved for the intervention with gender, age, stay at ICU, 
reason for admission, and comorbidities.
There was an analysis of the intervention efficacy based on time. The 
analysis results are shown in table 3. The fast glucose normalization was 
not associated in a statistically significant way with any of the factors stu-
died. There is a trend for fast glucose normalization after the intervention 
in women (HRc: 1.73; CI 95% 0.97-1.04, p = 0.180) and with clinical 
reason (HRc: 0.43; CI 95% 0.14-1.42, p = 0.170).
Discussion
As other authors have already stated9, understanding the predisposing 
factors previous to PN initiation will allow us to adapt the initial PN formu-
lation individually for each patient, thus reducing the risk of hyperglyce-
mia and its subsequent complications. For this reason, high glucose levels 
during PN administration, applying the described protocol, will orientate 
us towards the modification of glucose volume and/or the addition of 
insulin to the formulation. On the other hand, the study outcomes show 
that BMI is a parameter predicting the need for glucose restriction in the 
PN formulation. Therefore, those patients who present excess weight or 
obesity (BMI ≥ 25) are associated with hyperglycemia linked to the use 
of PN. Other studies have determined that previous surgery, renal failure 
and age are predictors of hyperglycemia, as well as obesity and excess 
weight4,6,12,18. We must point out that DM has been excluded from our 
analysis, because this is a factor that has determined glucose restriction in 
the formulation since the start, according to the application of the protocol 
described.
It is worth highlighting that no statistical association was observed in 
patients hospitalized in the ICU, against what was expected and des-
cribed by other authors4,6: this result could be explained by the reduced 
sample size of the study, because it is well known that metabolic altera-
tions of critical patients entail an elevation in glucose levels and insulin 
resistance due to an increase in glycogenolysis and gluconeogenesis. PN 
duration showed a trend towards intervention, but was not associated in a 
statistically significant way with a higher risk of hyperglycemia, unlike other 
authors who even associated it with longer hospital stays4. These factors, 
as well as the daily concentrations of glucose in blood, are available in 
clinical records for hospitalized patients, and therefore it would be conve-
nient to take them into account at the time of designing the PN formulation.
Special formulations for renal failure were initiated in seven patients. 
Due to the characteristics of their composition (reduced protein content), 
these require a low volume of glucose (100 g) to maintain an adequate 
ratio of non-protein calories per nitrogen gram. This glucose reduction is 
conducted when choosing the formulation, and therefore it has not been 
taken as a glucose restriction intervention, because there are other reasons 
for the intervention. In order to avoid this bias, these were initially excluded 
from logistical regression, but outcomes were not modified, so they were 
finally included in the analysis.
Glucose levels (every 8 hours) from 24 previous hours
3 values > 150mg/dl or 
2 values > 180mg/dl
Reduction of 50g  
glucose in the formulation
(Up to 100 g minimum)
Glucose levels (every 8 hours) from 24 previous hours
3 values > 150mg/dl or
2 values > 180mg/dl
Insulin addition in PN
Figure 1. Protocol for Glucose Reduction in PN.
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Table 1. Characteristics of patients (N = 58)






(number) 66.3 14.0 27 87
 ≤ 65-year-old 25 43.1
 > 65-year-old 33 56.9
BMI
(number) 26.3 4.1 16.2 35.2
Normal weight (< 25) 17 29.3
Overweight/Obesity (≥ 25) 41 20.7
Clinical Variables
Diabetes Mellitus 13 22.4
Previous Creatinine
(number) 1.2 1.0 0.4 6.3
 < 1.5 mg/dl 48 82.8
 ≥ 1.5 mg/dl 10 17.2
Comorbidities
Hypertension (YES) 32 55.2  
Dyslipidemia (YES) 15 25.9
Heart conditions (YES) 14 24.1
COPD (YES) 5 8.6
Reason for PN
Complication of GI tract neoplasia 14 24.1
Post-operative period after abdominal surgery 25 43.1
GI hemorrhage 9 15.5
Clinical deterioration due to sepsis 3 5.2
Oral intolerance due to liver disease 4 6.9
Oral intolerance for other reasons 3 5.2





Mean glucose in PN (g) 145.8 41.8 100 250
Glucose (g/kg/day) 2.2 0.8 1.1 4.4
Proteins (g/kg/day) 0.9 0.3 0.3 1.5
Lipids (g/kg/day) 0.8 0.3 0.3 1.7
Energy (Kcal/kg/day) 20 7 8 32.8
Basal Energy Expenditure (kcal/day) 1,402.2 273.2 920 2,252
Insulin YES 28 48.3
Units * 15.1 7.4 5 39.4
PN Duration (days) 12.8 10.9 2 51
Lab Test Variables
Glucose Pc previous to PN 129.3 42.6 59 260
Mean glucose Pc during PN 144.8 29.7 92.4 234.7
*Only patients receiving insulin are considered for this estimation. PN: parenteral nutrition; Pc: plasma concentration. Values are number (N), frequency (%), SD (standard deviation) 
and Min (minimum) & Max (maximum) range.
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In the arm of patients with intervention there are no patients with pre-
vious creatinine > 1.5 mg/dl, because a formulation with protein and glu-
cose restriction is indicated from the start. For this reasons, no intervention 
is required in the majority of these patients.
Some authors have observed that the composition of the parenteral 
formulation can have an impact on glucose levels in plasma (omega 3, 
glutamine)9; these factors have not been taken into account in this study, 
because lipid sources are the same in all cases, and no glutamine has 
Table 2. Logistical regression (excluding diabetic patients) (N = 45)
Without intervention (N = 27) With intervention (N = 18)
N % N % OR IC95% p-valor
Gender
Male 16 64 9 36 1 ref      
Female 11 55 9 45 1.45 0.44 4.83 0.541
Age
(number) 63.9 15.2 67 13.7 1.02 0.97 1.06 0.432
 ≤ 65 year-old 12 60 8 40 1 ref      
 > 65 year-old 15 60 10 40 1.00 0.30 3.32 1.00
BMI
(number) 25.3 4.2 28.7 2.9 1.29 1.05 1.58 0.014
Normal weight (< 25) 10 91.9 1 9.1 1 ref      
Overweight or Obese (≥ 25) 17 50 17 50 10.00 1.15 86.95 0.037
Previous 
Creatinine
(number) 1.3 0.9 0.9 0.3 0.39 0.12 1.35 0.140
 < 1.5 mg/dl 20 52.6 18 47.4
 ≥ 1.5 mg/dl 7 100
Hypertension
No 15 68.2 7 31.8 1 ref      
Yes 12 52.2 11 47.8 1.96 0.58 6.61 0.276
Dyslipidemia
No 20 60.6 13 39.4 1 ref      
Yes 7 58.3 5 41.7 1.09 0.28 4.21 0.891
Heart  
conditions
No 18 58.1 13 41.9 1 ref      
Yes 9 64.3 5 35.7 0.77 0.20 2.83 0.694
COPD




Complication of GI tract neoplasia 5 45.5 6 54.5 2.88 0.59 13.98 0.190
Post-operative period after abdominal surgery 10 58.8 7 41.2 1.68 0.40 6.96 0.474
Other* 12 70.6 5 29.4 1 ref      
ICU
No 17 65.4 9 34.6 1 ref      
Yes 10 52.6 9 47.4 1.7 0.39 5.70 0.860
Reason for 
admission
Surgical 20 60.6 13 39.4 1 ref      
Clinical 7 58.3 5 41.7 1.09 0.28 4.21 0.891
PN Duration (days) 10.9 9.8 16.6 13.0 1.04 0.98 1.11 0.114
Glucose previous to PN (OR x10 glucose units) 108.9 28.7 153 49.2 1.38 1.10 1.73 0.004
Mean PN glucose (OR x10 glucose units) 127.9 20.6 154.6 21.8 1.83 1.24 2.71 0.002
Insulin No 21 84 4 16 1 ref      
Yes 6 30 14 70 12.25 2.92 51.42 0.001
Insulin Units (only those on insulin) 8.1 1.9 16.3 7.9 2.70 1.05 6.94 0.038
A univariate logistical regression analysis was conducted in order to identify which individual characteristics were associated with the intervention. In each case, the raw odds 
ratio of the intervention was calculated, and its Confidence Interval at 95%, and the relevant p-value (Square Chi Test).
*Other: GI hemorrhage, clinical deterioration due to sepsis, oral intolerance due to hepatic disease, oral intolerance for other reasons.
PN: parenteral nutrition; Pc: plasma concentration, The values are number (N), frequency (%), OR (Odds ratio) and CI95% (Confidence Interval of 95%). Significant differences 
(p < 0.05).
been used. Moreover, we have no information about all the medica-
tion that could affect glucose levels (corticosteroids, vasopressor agents, 
etc.), given that a great proportion of the patients are in the ICU, and 
it is difficult for the Pharmacy Unit to obtain a record of the medication 
administered, as there is no system for medication distribution per units 
in this hospital unit.
The literature published regarding this shows that glucose levels > 180 
mg/dl previous to PN will entail an increase in pneumonia, renal failure, 
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and a higher duration of hospital stay5,9,11. However, it has been obser-
ved that an adequate management of hyperglycemia will reduce compli-
cations13. There has been no assessment of hyperglycemia complications 
in our study, but there has been intervention in all patients with glucose 
levels > 180 mg/dl.
Given that glucose concentrations in plasma are the main lab test value 
to be considered, it would be adequate to review the values of reference 
for hyperglycemia. In pre-diabetic or non-diagnosed patients, it could be 
considered that > 120 mg/dl values of glucose and of glycated haemog-
lobin (though the latter is not easily available in all non-diabetic patients) 
are predictors for intervention6. High glucose levels should not be taken 
into account if isolated; it is convenient to have continuous levels of high 
glucose (as stated in the protocol), because there is risk of hyperglycemia 
in any high-risk patient who is adequate for PN4. For this reason, there is no 
consensus among clinicians in terms of reducing the glucose volume in the 
PN for patients who present hyperglycemia3, and therefore it is important 
to determine glucose reference levels in order to avoid to a higher extent 
the development of hypoglycemia associated to a reduction in glucose 
intake. In this study, repeated values of > 150 mg/dl and/or > 180mg/dl 
show the safety of the intervention, because no hypoglycemia value has 
been recorded throughout. In our protocol, unlike other authors11,19,20 who 
have included insulin since PN initiation, glucose adjustments are laddered 
in order to prevent hypoglycemia. Even though it has been observed that 
there is a low incidence of hypoglycemia in patients on PN, its prevention 
Table 3. Factors associated with the efficacy of intervention
Non-diabetic patients with intervention (n = 18) HRc CI95% P value
Gender
Male 1 ref
Female 1.73 0.77 3.88 0.180
Age
(number) 1.00 0.97 1.04 0.607
 ≤ 65-year-old 1 ref
 > 65-year-old 0.92 0.42 2.00 0.824
BMI
(number) 1.04 0.92 1.17 0.497
Normal weight (< 25) 1 ref
Overweight or Obese ≥ 25) 0.71 0.24 2.06 0.529
Previous Creatinine
(number) 0.78 0.27 2.28 0.661
 < 1,5 mg/dl 1 ref
 ≥ 1,5 mg/dl 0.53 0.11 2.58 0.436
Hypertension
No 1 ref
Yes 0.64 0.28 1.47 0.295
Dyslipidemia
No 1 ref
Yes 1.52 0.64 3.64 0.343
Heart conditions
No 1 ref
Yes 1.05 0.36 2.99 0.932
COPD
No 1 ref
Yes 2.02 0.40 10.02 0.389
Reason for PN
Complication of GI tract neoplasia 0.87 0.30 2.48 0.801




Yes 1.62 0.65 4.03 0.302
Reason for admission
Surgical 1 ref
Clinical 0.43 0.14 1.42 0.170
Glucose previous to PN (OR x10 glucose units) 0.98 0.89 1.06 0.606
Mean PN glucose (OR x10 glucose units) 0.84 0.71 1.01 0.071
Insulin
No 1 ref
Yes 0.59 0.23 1.49 0.264
Insulin Units 0.95 0.89 1.01 0.129
Mean glucose (g) in PN (HR x10 Glucose Units) 1.14 0.95 1.38 0.151
A Cox Regression analysis was conducted, considering the time from intervention until stabilization as time scale, and stabilization as final outcome. Hazard ratio was esti-
mated, Confidence Interval at 95%, and the relevant p-value (Chi Square Test). It was adjusted by the diabetes variable in the model.
*Other: GI hemorrhage, clinical deterioration due to sepsis, oral intolerance due to hepatic disease, oral intolerance for other reasons. PN: parenteral nutrition, PC: plasma 
concentration. **Cox Regression analysis, adjusted by diabetes. Values are HR (Hazard ratio) and CI95% (95% Confidence Interval). Significant differences (p < 0.05).
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In conclusion, hyperglycemia is a very frequent alteration in patients 
receiving PN, and it requires close management. The standardization of 
formulations and inclusion of interventions in protocols will provide quality 
and safety to the process. Glucose levels previous to PN, diabetes, and 
BMI > 25 are predictors of hyperglycemia; therefore, an early intervention to 
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Contribution to scientific literature
The results show the high incidence of hyperglycemia in diabetic 
patients, with high glycemic values prior to parenteral nutrition and 
with BMI > 25, and therefore the need for early intervention.
The values of BMI > 25 are added as predictors to the interven-
tion protocol and, together with glycemia before parenteral nutrition 
and diabetes, guide the design of parenteral nutrition to improve the 
control of hyperglycemia.
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is important in patients with risk factors: longer PN nutrition and insulin, 
diabetic patients, and those in the ICU21.
The following are considered potential biases in this observational stu-
dy: data from daily clinical practice have been collected, where the same 
protocol is used for all patients, there has been a consecutive inclusion of all 
patients, and no patients have been excluded who could have altered the 
outcomes. Moreover, low protein contents (0.95 g/kg/day, excluding the 
seven patients with renal failure), probably due to the widespread practice 
in our centre of choosing initially (off the morning working hours) marketed 
three-chamber formulations with low protein contents, could have a negati-
ve impact on glucose level control, due to the insulinotropic effect of some 
amino acids and the insulin resistance induced by this low protein intake22-25. 
The lack of more conclusive results show the convenience of being more 
conservative in terms of initiation therapy, and not restrictive in terms of 
glucose contents, in order to prevent the risk of hypoglycemia and meet 
the needs.
High glucose levels have been associated with a higher risk of compli-
cations4, and therefore it is important to identify those patients with risk of 
hyperglycemia associated with PN, and to prevent any complications that 
could appear during the period of administration. The benefit of glucose 
control is particularly important in patients without diagnosis of diabetes, be-
cause it has been observed that mortality associated with hyperglycemia is 
highly superior in these patients than in already known diabetic patients26,27. 
Future research should include more patients in specific populations, in order 
to reach conclusive outcomes that will be useful for daily clinical practice.
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